Studying Biomarkers in Samples From Younger Patients With Wilms Tumor

Children's Oncology Group

Status

Completed

Conditions

Kidney Cancer

Treatments

Other: medical chart review

Genetic: nucleic acid amplification

Other: diagnostic laboratory biomarker analysis

Genetic: DNA analysis

Study type

Observational

Funder types

NETWORK

NIH

Identifiers

NCT01576198

NCI-2012-00725 (Registry Identifier)

AREN11B3 (Other Identifier)

COG-AREN11B3 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of blood, tissue, or bone marrow from patients with cancer in the laboratory may help doctors to learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in samples from younger patients with Wilms tumor.

Full description

OBJECTIVES:

To analyze 250 favorable-histology Wilms tumor (FHWT) samples from patients registered on NWTS4 for gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q by subtelomeric multiplex ligation-dependent probe amplification (MLPA), and to determine their association with relapse-free and overall survival.
To develop a robust multiplex MLPA test using multiple synthesized probes to those targets identified as significantly associated with relapse in Aim 1.
To validate the multiplex MLPA test designed and tested in Aim 2 on an independent set of 1727 FHWT and 250 anaplastic WT registered on NWTS-5.

OUTLINE: Archived DNA samples are analyzed for gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q by MLPA. Assay results are then researched for accuracy, clinical validity, sensitivity, precision, and potential analytical interferences.

Enrollment

2,227 estimated patients

Sex

All

Ages

Under 120 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS: